The boom in weight-loss drugs and their massive impact on biomanufacturing real estate continues.  Novo Nordisk plans to invest $1.5B in new biomanufacturing capacity near its existing facility in Clayton, North Carolina, roughly 35 miles southeast of Durham. Announced during an afternoon press conference Monday and first reported by Triangle Business Journal, it’s a significant development,